Month: September 2025

Nordic Fibreboard AS (registry code: 11421437, address: Rääma tn 31, Pärnu, 80044 Estonia; the Company) hereby announces the additional public offering of its shares. Only existing shareholders of the Company are entitled to participate in the offering, who will be granted pre-emptive subscription rights in proportion to the number of shares held by them. The offering is based on an information document prepared by the Company, which is available on the Company’s website: https://www.nordicfibreboard.com/investor/stock-information/. The information document has been prepared in accordance with Article 1(4)(db) of Regulation (EU) 2017/1129 of the European Parliament and of the Council (the “Prospectus Regulation“), including the information set out in Annex IX to the Prospectus Regulation. Accordingly, no prospectus for...

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor UpdateFaraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: Unseen Interior and Product Highlights of the FX Super One to Be Unveiled on 919 Futurist Day & Shareholders’ DayNumerous Company updates will be given at the 919 event including details on C10 & C (Crypto), the Company’s three growth engines, including the C10 Treasury; its roadmap for capital value realization; and the deployment strategy for FF EAI Vehicle Chain products.LOS ANGELES, Sept. 07, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global...

HIBRUKA (Orelabrutinib)Approval of HIBRUKA (Orelabrutinib) for the Treatment of R/R MZL in SingaporeBEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (R/R MZL). Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare said, “We are excited to obtain a second indication approval in Singapore. As a highly selective BTK inhibitor, orelabrutinib has demonstrated good efficacy and safety in the treatment of R/R MZL. The approval in Singapore will offer a new treatment option to local lymphoma patients. In addition...

New Ultra Lith KrF Track System Delivers High-Throughput Performance with Proprietary Platform Design, Driving Advanced Process Control for Mature-node Lithography Applications FREMONT, Calif., Sept. 07, 2025 (GLOBE NEWSWIRE) —  ACM Research, Inc. (“ACM”) (NASDAQ: ACMR), a leading supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, today announced the launch of its first Ultra Lith KrF track system, designed to support front-end semiconductor manufacturing. The new system expands ACM’s lithography product line and delivers high-throughput performance, advanced thermal control, and real-time process control and monitoring. The first system was shipped to a leading Chinese logic wafer fab customer in September 2025. ACM’s Ultra Lith KrF track system builds on the proven architecture...

TORONTO, Sept. 07, 2025 (GLOBE NEWSWIRE) — Abaxx Technologies Inc. (CBOE:ABXX)(OTCQX:ABXXF) (“Abaxx” or the “Company”), a financial software and market infrastructure company, majority shareholder of Abaxx Singapore Pte Ltd. (“Abaxx Singapore”), the owner of Abaxx Commodity Exchange and Clearinghouse (individually, “Abaxx Exchange” and “Abaxx Clearing”), and producer of the SmarterMarkets™ Podcast, today announced that Abaxx Exchange and Qingdao International Energy Exchange, a key energy trading platform in China, intend to explore strategic collaboration in the physical liquefied natural gas (LNG) market. By combining Abaxx’s physically-deliverable liquefied natural gas (LNG) futures and clearing infrastructure with Qingdao International Energy Exchange’s established position in China’s energy markets, the collaboration...

NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT. Investor Webcast & Conference Call InformationTo access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.  A live webcast may be accessed through the Investors and Media section of the Company’s website, www.dianthustx.com....

SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that company’s product, recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) has achieved positive results in a multi-center, randomized, double-blind, parallel, placebo-controlled pivotal registrational Phase 3 clinical study (study number: JS005-005-III-PsO) for the treatment of moderate to severe plaque psoriasis. Both the co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements. Junshi Biosciences plans to submit the new drug application of this product to the regulatory authorities...

– 80% of post-surgical hypoparathyroidism participants achieved concomitant blood and 24-hour urine calcium in the normal reference range within 5 days of encaleret treatment initiation compared to 0% of participants on conventional therapy at baseline – Encaleret was well-tolerated with no serious adverse events reported over the study period – Based on these findings, BridgeBio intends to initiate a registrational clinical study of encaleret, an orally-administered investigational therapy, in chronic hypoparathyroidism in 2026 PALO ALTO, Calif., Sept. 06, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that encaleret showed parathyroid hormone (PTH)-independent normalization of blood...

SAINT-BRUNO-DE-MONTARVILLE, Quebec, Sept. 05, 2025 (GLOBE NEWSWIRE) — Colabor Group Inc. (“Colabor” or the “Company”) (TSX: GCL) today announced that it has entered into a forbearance agreement (the “Agreement”) with its principal lenders, including The Toronto-Dominion Bank, Bank of Montreal, and The Bank of Nova Scotia (collectively, the “Lenders”), under its amended and restated senior first-ranking secured credit facility (the “A&R Credit Facility”). In addition, the Company has entered into separate forbearance agreements (the “IQ Forbearance Agreements” and, together with the Agreement, the “Forbearance Agreements”) with Investissement Québec (“IQ”) under its subordinated and highly subordinated credit facilities with IQ (the “IQ Credit Facilities”). Under the terms of the Forbearance Agreements, the Lenders and IQ have...